Sawai Pharmaceutical expects its Upsher-Smith affiliate, by its 2022-2023 financial year, to generate more than $50m in annual sales from two migraine brands recently acquired from Dr Reddy’s. That will be well over double the less than $20m that the Japanese group expects from the Zembrace SymTouch and Tosymra sumatriptan brands in its current financial year ending on 31 March 2020.
Upsher-Smith paid Reddy’s $70m upfront, plus another $40.5m in near-term milestones and financial considerations, for the Zembrace SymTouch 3mg injectable, which is already on the US market, and the Tosymra 10mg nasal spray, which is not. Sawai said Upsher-Smith had scheduled a launch for the Tosymra migraine remedy before the end of this year